BioPharma Dive – AI / Data
FDA clears Denali drug in ‘clear step’ for rare disease biotechs
The approval of Denali’s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led to criticism of the FDA’s stance on rare disease therapies.